Table No.
|
Table Title
|
Table 1.1-1
|
Patent information of aminopyralid in some countries/regions, as of July 2017
|
Table 1.1-2
|
Registration information of aminopyralid in China, as of July 2017
|
Table 1.1-3
|
Registration information of aminopyralid in Finland, as of July 2017
|
Table 1.1-4
|
Registration information of aminopyralid in Denmark, as of July 2017
|
Table 1.1-5
|
Registration information of aminopyralid in Canada, as of July 2017
|
Table 1.1-6
|
Registration information of aminopyralid in France, as of July 2017
|
Table 1.1-7
|
Registration information of aminopyralid in Uruguay, as of July 2017
|
Table 1.1-8
|
Registration information of aminopyralid in Australia, as of July 2017
|
Table 1.1-9
|
Registration information of aminopyralid in Switzerland, as of July 2017
|
Table 1.1-10
|
Registration information of aminopyralid in Argentina, as of July 2017
|
Table 1.1-11
|
Registration information of aminopyralid in South Africa, as of July 2017
|
Table 1.2-1
|
Patent information of flucetosulfuron in some countries/regions, as of July 2017
|
Table 1.2-2
|
Registration information of flucetosulfuron in China, as of July 2017
|
Table 1.3-1
|
Patent information of flufenpyr-ethyl in some countries/regions, as of July 2017
|
Table 1.4-1
|
Patent information of foramsulfuron in some countries/regions, as of July 2017
|
Table 1.4-2
|
Registration information of foramsulfuron in Argentina, as of July 2017
|
Table 1.4-3
|
Registration information of foramsulfuron in Denmark, as of July 2017
|
Table 1.4-4
|
Registration information of foramsulfuron in Australia, as of July 2017
|
Table 1.4-5
|
Registration information of foramsulfuron in Belgium, as of July 2017
|
Table 1.4-6
|
Registration information of foramsulfuron in Canada, as of July 2017
|
Table 1.4-7
|
Registration information of foramsulfuron in Chile, as of July 2017
|
Table 1.4-8
|
Registration information of foramsulfuron in France, as of July 2017
|
Table 1.4-9
|
Registration information of foramsulfuron in Greece, as of July 2017
|
Table 1.4-10
|
Registration information of foramsulfuron in the Netherlands, as of July 2017
|
Table 1.4-11
|
Registration information of foramsulfuron in Switzerland, as of July 2017
|
Table 1.4-12
|
Registration information of foramsulfuron in Uruguay, as of July 2017
|
Table 1.5-1
|
Patent information of metamifop in some countries/regions, as of July 2017
|
Table 1.5-2
|
Registration information of metamifop in China, as of July 2017
|
Table 1.5-3
|
Registration information of metamifop in Uruguay, as of July 2017
|
Table 1.6-1
|
Patent information of orthosulfamuron in some countries/regions, as of July 2017
|
Table 1.6-2
|
Registration information of orthosulfamuron in China, as of July 2017
|
Table 1.6-3
|
Registration information of orthosulfamuron in Brazil, as of July 2017
|
Table 1.7-1
|
Patent information of penoxsulam in some countries/regions, as of July 2017
|
Table 1.7-2
|
Registration information of penoxsulam in Argentina, as of July 2017
|
Table 1.7-3
|
Registration information of penoxsulam in Brazil, as of July 2017
|
Table 1.7-4
|
Registration information of penoxsulam in Chile, as of July 2017
|
Table 1.7-5
|
Registration information of penoxsulam in China, as of July 2017
|
Table 1.7-6
|
Registration information of penoxsulam in France, as of July 2017
|
Table 1.7-7
|
Registration information of penoxsulam in Switzerland, as of July 2017
|
Table 1.7-8
|
Registration information of penoxsulam in Uruguay, as of July 2017
|
Table 1.8-1
|
Patent information of pinoxaden in some countries/regions, as of July 2017
|
Table 1.8-2
|
Registration information of pinoxaden in Argentina, as of July 2017
|
Table 1.8-3
|
Registration information of pinoxaden in South Africa, as of July 2017
|
Table 1.8-4
|
Registration information of pinoxaden in Australia, as of July 2017
|
Table 1.8-5
|
Registration information of pinoxaden in Belgium, as of July 2017
|
Table 1.8-6
|
Registration information of pinoxaden in Canada, as of July 2017
|
Table 1.8-7
|
Registration information of pinoxaden in Chile, as of July 2017
|
Table 1.8-8
|
Registration information of pinoxaden in China, as of July 2017
|
Table 1.8-9
|
Registration information of pinoxaden in Finland, as of July 2017
|
Table 1.8-10
|
Registration information of pinoxaden in France, as of July 2017
|
Table 1.8-11
|
Registration information of pinoxaden in the Netherlands, as of July 2017
|
Table 1.8-12
|
Registration information of pinoxaden in Switzerland, as of July 2017
|
Table 1.8-13
|
Registration information of pinoxaden in Uruguay, as of July 2017
|
Table 1.9-1
|
Patent information of pyrasulfotole in some countries/regions, as of July 2017
|
Table 1.9-2
|
Registration information of pyrasulfotole in Canada, as of July 2017
|
Table 1.9-3
|
Registration information of pyrasulfotole in Australia, as of July 2017
|
Table 1.9-4
|
Registration information of pyrasulfotole in South Africa, as of July 2017
|
Table 1.10-1
|
Patent information of pyroxasulfone in some countries/regions, as of July 2017
|
Table 1.10-2
|
Registration information of pyroxasulfone in Canada, as of July 2017
|
Table 1.10-3
|
Registration information of pyroxasulfone in Australia, as of July 2017
|
Table 1.10-4
|
Registration information of pyroxasulfone in South Africa, as of July 2017
|
Table 1.11-1
|
Patent information of pyroxsulam in some countries/regions, as of July 2017
|
Table 1.11-2
|
Registration information of pyroxsulam in China, as of July 2017
|
Table 1.11-3
|
Registration information of pyroxsulam in Belgium, as of July 2017
|
Table 1.11-4
|
Registration information of pyroxsulam in Brazil, as of July 2017
|
Table 1.11-5
|
Registration information of pyroxsulam in Canada, as of July 2017
|
Table 1.11-6
|
Registration information of pyroxsulam in France, as of July 2017
|
Table 1.11-7
|
Registration information of pyroxsulam in the Netherlands, as of July 2017
|
Table 1.11-8
|
Registration information of pyroxsulam in Australia, as of July 2017
|
Table 1.11-9
|
Registration information of pyroxsulam in Switzerland, as of July 2017
|
Table 1.11-10
|
Registration information of pyroxsulam in Denmark, as of July 2017
|
Table 1.11-11
|
Registration information of pyroxsulam in Greece, as of July 2017
|
Table 1.11-12
|
Registration information of pyroxsulam in South Africa, as of July 2017
|
Table 1.12-1
|
Patent information of saflufenacil in some countries/regions, as of July 2017
|
Table 1.12-2
|
Registration information of saflufenacil in China, as of July 2017
|
Table 1.12-3
|
Registration information of saflufenacil in Brazil, as of July 2017
|
Table 1.12-4
|
Registration information of saflufenacil in Canada, as of July 2017
|
Table 1.12-5
|
Registration information of saflufenacil in Uruguay, as of July 2017
|
Table 1.12-6
|
Registration information of saflufenacil in Australia, as of July 2017
|
Table 1.12-7
|
Registration information of saflufenacil in Chile, as of July 2017
|
Table 1.12-8
|
Registration information of saflufenacil in Argentina, as of July 2017
|
Table 1.13-1
|
Patent information of tembotrione in some countries/regions, as of July 2017
|
Table 1.13-2
|
Registration information of tembotrione in Belgium, as of July 2017
|
Table 1.13-3
|
Registration information of tembotrione in South Africa, as of July 2017
|
Table 1.13-4
|
Registration information of tembotrione in Canada, as of July 2017
|
Table 1.13-5
|
Registration information of tembotrione in Chile, as of July 2017
|
Table 1.13-6
|
Registration information of tembotrione in France, as of July 2017
|
Table 1.13-7
|
Registration information of tembotrione in the Netherlands, as of July 2017
|
Table 1.13-8
|
Registration information of tembotrione in Switzerland, as of July 2017
|
Table 1.14-1
|
Patent information of thiencarbazone-methyl in some countries/regions, as of July 2017
|
Table 1.14-2
|
Registration information of thiencarbazone-methyl in Belgium, as of July 2017
|
Table 1.14-3
|
Registration information of thiencarbazone-methyl in Canada, as of July 2017
|
Table 1.14-4
|
Registration information of thiencarbazone-methyl in France, as of July 2017
|
Table 1.14-5
|
Registration information of thiencarbazone-methyl in the Netherlands, as of July 2017
|
Table 1.14-6
|
Registration information of thiencarbazone-methyl in Uruguay, as of July 2017
|
Table 1.14-7
|
Registration information of thiencarbazone-methyl in China, as of July 2017
|
Table 1.15-1
|
Patent information of topramezone in some countries/regions, as of July 2017
|
Table 1.15-2
|
Registration information of topramezone in Argentina, as of July 2017
|
Table 1.15-3
|
Registration information of topramezone in South Africa, as of July 2017
|
Table 1.15-4
|
Registration information of topramezone in Canada, as of July 2017
|
Table 1.15-5
|
Registration information of topramezone in Chile, as of July 2017
|
Table 1.15-6
|
Registration information of topramezone in China, as of July 2017
|
Table 1.15-7
|
Registration information of topramezone in Australia, as of July 2017
|
Table 2.1-1
|
Patent information of bistrifluron in some countries/regions, as of July 2017
|
Table 2.1-2
|
Registration information of bistrifluron in Australia, as of July 2017
|
Table 2.1-3
|
Registration information of bistrifluron in Argentina, as of July 2017
|
Table 2.2-1
|
Patent information of chlorantraniliprole in some countries/regions, as of July 2017
|
Table 2.2-2
|
Registration information of chlorantraniliprole in China, as of July 2017
|
Table 2.2-3
|
Registration information of chlorantraniliprole in Canada, as of July 2017
|
Table 2.2-4
|
Registration information of chlorantraniliprole in France, as of July 2017
|
Table 2.2-5
|
Registration information of chlorantraniliprole in the Netherlands, as of July 2017
|
Table 2.2-6
|
Registration information of chlorantraniliprole in Australia, as of July 2017
|
Table 2.2-7
|
Registration information of chlorantraniliprole in Switzerland, as of July 2017
|
Table 2.2-8
|
Registration information of chlorantraniliprole in South Africa, as of July 2017
|
Table 2.3-1
|
Patent information of clothianidin in some countries/regions, as of July 2017
|
Table 2.3-2
|
Registration information of clothianidin in Chile, as of July 2017
|
Table 2.3-3
|
Registration information of clothianidin in Denmark, as of July 2017
|
Table 2.3-4
|
Registration information of clothianidin in South Africa, as of July 2017
|
Table 2.3-5
|
Registration information of clothianidin in Australia, as of July 2017
|
Table 2.3-6
|
Registration information of clothianidin in Belgium, as of July 2017
|
Table 2.3-7
|
Registration information of clothianidin in Canada, as of July 2017
|
Table 2.3-8
|
Registration information of clothianidin in China, as of July 2017
|
Table 2.3-9
|
Registration information of clothianidin in Greece, as of July 2017
|
Table 2.3-10
|
Registration information of clothianidin in the Netherlands, as of July 2017
|
Table 2.3-11
|
Registration information of clothianidin in Switzerland, as of July 2017
|
Table 2.3-12
|
Registration information of clothianidin in Uruguay, as of July 2017
|
Table 2.3-13
|
Registration information of clothianidin in France, as of July 2017
|
Table 2.4-1
|
Patent information of flubendiamide in some countries/regions, as of July 2017
|
Table 2.4-2
|
Registration information of flubendiamide in Argentina, as of July 2017
|
Table 2.4-3
|
Registration information of flubendiamide in Australia, as of July 2017
|
Table 2.4-4
|
Registration information of flubendiamide in South Africa, as of July 2017
|
Table 2.4-5
|
Registration information of flubendiamide in Chile, as of July 2017
|
Table 2.4-6
|
Registration information of flubendiamide in China, as of July 2017
|
Table 2.4-7
|
Registration information of flubendiamide in Uruguay, as of July 2017
|
Table 2.5-1
|
Patent information of metofluthrin in some countries/regions, as of July 2017
|
Table 2.5-2
|
Registration information of metofluthrin in Australia, as of July 2017
|
Table 2.5-3
|
Registration information of metofluthrin in Canada, as of July 2017
|
Table 2.5-4
|
Registration information of metofluthrin in China, as of July 2017
|
Table 2.5-5
|
Registration information of metofluthrin in the Netherlands, as of July 2017
|
Table 2.6-1
|
Patent information of pyrifluquinazon in some countries/regions, as of July 2017
|
Table 2.7-1
|
Patent information of spirotetramat in some countries/regions, as of July 2017
|
Table 2.7-2
|
Registration information of spirotetramat in Argentina, as of July 2017
|
Table 2.7-3
|
Registration information of spirotetramat in Australia, as of July 2017
|
Table 2.7-4
|
Registration information of spirotetramat in Denmark, as of July 2017
|
Table 2.7-5
|
Registration information of spirotetramat in South Africa, as of July 2017
|
Table 2.7-6
|
Registration information of spirotetramat in Belgium, as of July 2017
|
Table 2.7-7
|
Registration information of spirotetramat in Canada, as of July 2017
|
Table 2.7-8
|
Registration information of spirotetramat in Chile, as of July 2017
|
Table 2.7-9
|
Registration information of spirotetramat in China, as of July 2017
|
Table 2.7-10
|
Registration information of spirotetramat in France, as of July 2017
|
Table 2.7-11
|
Registration information of spirotetramat in Greece, as of July 2017
|
Table 2.7-12
|
Registration information of spirotetramat in the Netherlands, as of July 2017
|
Table 2.7-13
|
Registration information of spirotetramat in Uruguay, as of July 2017
|
Table 2.7-14
|
Registration information of spirotetramat in Switzerland, as of July 2017
|
Table 3.1-1
|
Patent information of amisulbrom in some countries/regions, as of July 2017
|
Table 3.1-2
|
Registration information of amisulbrom in Belgium, as of July 2017
|
Table 3.1-3
|
Registration information of amisulbrom in Franch, as of July 2017
|
Table 3.1-4
|
Registration information of amisulbrom in Finland, as of July 2017
|
Table 3.1-5
|
Registration information of amisulbrom in the Netherlands, as of July 2017
|
Table 3.1-6
|
Registration information of amisulbrom in Switzerland, as of July 2017
|
Table 3.1-7
|
Registration information of amisulbrom in China, as of July 2017
|
Table 3.1-8
|
Registration information of amisulbrom in Australia, as of July 2017
|
Table 3.2-1
|
Patent information of benalaxyl-M in some countries/regions, as of July 2017
|
Table 3.2-2
|
Registration information of benalaxyl-M in Argentina, as of July 2017
|
Table 3.2-3
|
Registration information of benalaxyl-M in Belgium, as of July 2017
|
Table 3.2-4
|
Registration information of benalaxyl-M in France, as of July 2017
|
Table 3.2-5
|
Registration information of benalaxyl-M in the Netherlands, as of July 2017
|
Table 3.2-6
|
Registration information of benalaxyl-M in Switzerland, as of July 2017
|
Table 3.3-1
|
Patent information of fenpyrazamine in some countries/regions, as of July 2017
|
Table 3.3-2
|
Registration information of fenpyrazamine in Australia, as of July 2017
|
Table 3.3-3
|
Registration information of fenpyrazamine in Chile, as of July 2017
|
Table 3.3-4
|
Registration information of fenpyrazamine in Denmark, as of July 2017
|
Table 3.3-5
|
Registration information of fenpyrazamine in Belgium, as of July 2017
|
Table 3.3-6
|
Registration information of fenpyrazamine in France, as of July 2017
|
Table 3.3-7
|
Registration information of fenpyrazamine in the Netherlands, as of July 2017
|
Table 3.4-1
|
Patent information of fluopicolide in some countries/regions, as of July 2017
|
Table 3.4-2
|
Registration information of fluopicolide in Argentina, as of July 2017
|
Table 3.4-3
|
Registration information of fluopicolide in Australia, as of July 2017
|
Table 3.4-4
|
Registration information of fluopicolide in Denmark, as of July 2017
|
Table 3.4-5
|
Registration information of fluopicolide in South Africa, as of July 2017
|
Table 3.4-6
|
Registration information of fluopicolide in Belgium, as of July 2017
|
Table 3.4-7
|
Registration information of fluopicolide in Brazil, as of July 2017
|
Table 3.4-8
|
Registration information of fluopicolide in Canada, as of July 2017
|
Table 3.4-9
|
Registration information of fluopicolide in Chile, as of July 2017
|
Table 3.4-10
|
Registration information of fluopicolide in China, as of July 2017
|
Table 3.4-11
|
Registration information of fluopicolide in Finland, as of July 2017
|
Table 3.4-12
|
Registration information of fluopicolide in France, as of July 2017
|
Table 3.4-13
|
Registration information of fluopicolide in the Netherlands, as of July 2017
|
Table 3.4-14
|
Registration infromation of fluopicolide in Switzerland, as of July 2017
|
Table 3.4-15
|
Registration information of fluopicolide in Uruguay, as of July 2017
|
Table 3.5-1
|
Patent information of fluoxastrobin in some countries/regions, as of July 2017
|
Table 3.5-2
|
Registration information of fluoxastrobin in Argentina, as of July 2017
|
Table 3.5-3
|
Registration information of fluoxastrobin in Belgium, as of July 2017
|
Table 3.5-4
|
Registration information of fluoxastrobin in Canada, as of July 2017
|
Table 3.5-5
|
Registration information of fluoxastrobin in France, as of July 2017
|
Table 3.5-6
|
Registration information of fluoxastrobin in the Netherlands, as of July 2017
|
Table 3.5-7
|
Registration information of fluoxastrobin in Switzerland, as of July 2017
|
Table 3.5-8
|
Registration information of fluoxastrobin in Uruguay, as of July 2017
|
Table 3.5-9
|
Registration information of fluoxastrobin in China, as of July 2017
|
Table 3.6-1
|
Patent information of isotianil in some countries/regions, as of July 2017
|
Table 3.7-1
|
Patent information of mandipropamid in some countries/regions, as of July 2017
|
Table 3.7-2
|
Registration information of mandipropamid in Belgium, as of July 2017
|
Table 3.7-3
|
Registration information of mandipropamid in Brazil, as of July 2017
|
Table 3.7-4
|
Registration information of mandipropamid in China, as of July 2017
|
Table 3.7-5
|
Registration information of mandipropamid in Canada, as of July 2017
|
Table 3.7-6
|
Registration information of mandipropamid in France, as of July 2017
|
Table 3.7-7
|
Registration information of mandipropamid in Finland, as of July 2017
|
Table 3.7-8
|
Registration information of mandipropamid in the Nertherlands, as of July 2017
|
Table 3.7-9
|
Registration information of mandipropamid in Australia, as of July 2017
|
Table 3.7-10
|
Registration information of mandipropamid in Switzerland, as of July 2017
|
Table 3.7-11
|
Registration information of mandipropamid in Denmark, as of July 2017
|
Table 3.7-12
|
Registration information of mandipropamid in Chile, as of July 2017
|
Table 3.7-13
|
Registration information of mandipropamid in Argentina, as of July 2017
|
Table 3.7-14
|
Registration information of mandipropamid in South Africa, as of July 2017
|
Table 3.8-1
|
Patent information of metalaxyl-M in some countries/regions, as of July 2017
|
Table 3.8-2
|
Registration information of metalaxyl-M in Argentina, as of July 2017
|
Table 3.8-3
|
Registration information of metalaxyl-M in Chile, as of July 2017
|
Table 3.8-4
|
Registration information of metalaxyl-M in Denmark, as of July 2017
|
Table 3.8-5
|
Registration information of metalaxyl-M in South Africa, as of July 2017
|
Table 3.8-6
|
Registration information of metalaxyl-M in Australia, as of July 2017
|
Table 3.8-7
|
Registration information of metalaxyl-M in Belgium, as of July 2017
|
Table 3.8-8
|
Registration information of metalaxyl-M in Brazil, as of July 2017
|
Table 3.8-9
|
Registration information of metalaxyl-M in Canada, as of July 2017
|
Table 3.8-10
|
Registration information of metalaxyl-M in China, as of July 2017
|
Table 3.8-11
|
Registration information of metalaxyl-M in Finland, as of July 2017
|
Table 3.8-12
|
Registration information of metalaxyl-M in Greece, as of July 2017
|
Table 3.8-13
|
Registration information of metalaxyl-M in the Netherlands, as of July 2017
|
Table 3.8-14
|
Registration information of metalaxyl-M in Switzerland, as of July 2017
|
Table 3.8-15
|
Registration information of metalaxyl-M in Uruguay, as of July 2017
|
Table 3.8-16
|
Registration information of metalaxyl-M in France, as of July 2017
|
Table 3.9-1
|
Patent information of metrafenone in some countries/regions, as of July 2017
|
Table 3.9-2
|
Registration information of metrafenone in Australia, as of July 2017
|
Table 3.9-3
|
Registration information of metrafenone in Argentina, as of July 2017
|
Table 3.9-4
|
Registration information of metrafenone in Denmark, as of July 2017
|
Table 3.9-5
|
Registration information of metrafenone in South Africa, as of July 2017
|
Table 3.9-6
|
Registration information of metrafenone in Belgium, as of July 2017
|
Table 3.9-7
|
Registration information of metrafenone in Canada, as of July 2017
|
Table 3.9-8
|
Registration information of metrafenone in Chile, as of July 2017
|
Table 3.9-9
|
Registration information of metrafenone in Switzerland, as of July 2017
|
Table 3.9-10
|
Registration information of metrafenone in China, as of July 2017
|
Table 3.9-11
|
Registration information of metrafenone in the Netherlands, as of July 2017
|
Table 3.9-12
|
Registration information of metrafenone in France, as of July 2017
|
Table 3.10-1
|
Patent information of penflufen in some countries/regions, as of July 2017
|
Table 3.10-2
|
Registration information of penflufen in China, as of July 2017
|
Table 3.10-3
|
Registration information of penflufen in Canada, as of July 2017
|
Table 3.10-4
|
Registration information of penflufen in the Netherlands, as of July 2017
|
Table 3.10-5
|
Registration information of penflufen in Australia, as of July 2017
|
Table 3.11-1
|
Patent information of valifenalate in some countries/regions, as of July 2017
|
Table 3.11-2
|
Registration information of valifenalate in Belgium, as of July 2017
|
Table 3.11-3
|
Registration information of valifenalate in France, as of July 2017
|
Table 3.11-4
|
Registration information of valifenalate in Switzerland, as of July 2017
|
Table 4.1-1
|
Patent information of cyprosulfamide in some countries/regions, as of July 2017
|
Table 4.1-2
|
Registration information of cyprosulfamide in Belgium, as of July 2017
|
Table 4.1-3
|
Registration information of cyprosulfamide in Canada, as of July 2017
|
Table 4.1-4
|
Registration information of cyprosulfamide in Uruguay, as of July 2017
|
Table 4.1-5
|
Registration information of cyprosulfamide in Argentina, as of July 2017
|